{
    "title": "103_hr1926",
    "content": "The \"National Narcotics Leadership Act Amendments of 1993\" allows the Director to request funding for specific initiatives in line with the President's priorities for the National Drug Control Strategy. Additionally, it includes provisions for reprogramming reports and restrictions on office personnel. SEC. 3 amends the National Narcotics Leadership Act to require quarterly reports on fund reprogramming over $5,000,000 and prohibits political campaigning by certain federal officers in the Office of National Drug Control Policy. Section 1005(a) of the National Narcotics Leadership Act of 1988 is amended to include an evaluation of Federal drug control effectiveness in the National Drug Control Strategy, assessing reduction of drug use in various populations and workplaces. The amended Section 1005(a) of the National Narcotics Leadership Act of 1988 evaluates Federal drug control effectiveness by assessing drug use reduction in high-risk populations and workplaces, measuring drug availability through quantities, cultivation, seizures, and price changes. The evaluation of Federal drug control effectiveness includes assessing the cultivation and destruction of coca, seizures of heroin and cocaine, destruction of cocaine processing labs, changes in drug prices and purity, diversion of controlled substances, and the effectiveness of technology programs at improving drug detection capabilities at ports of entry. Additionally, it assesses the reduction of drug consequences, such as the burden on hospital emergency rooms in the United States. The assessment of the reduction of drug consequences in the United States includes estimating burdens on hospital emergency rooms, national healthcare costs, drug-related crime, and the contribution of drugs to the underground economy. Additionally, the status of drug treatment in the United States is determined. The assessment includes estimating burdens on hospital emergency rooms, national healthcare costs, drug-related crime, and the contribution of drugs to the underground economy. It also determines the status of drug treatment in the United States, including treatment capacity, availability for specific groups, estimated number of beneficiaries, and treatment success. The Director assesses the success and quality of drug treatment programs for specific groups like intravenous drug users and pregnant women, estimating the number of beneficiaries and evaluating treatment effectiveness federally and within each State. The Director evaluates drug treatment programs for different groups, assesses measurement instruments, and identifies factors limiting treatment availability. The Director evaluates drug treatment programs for different groups, assesses limitations in treatment availability, and proposes remedies to make treatment more accessible. Federal agencies must cooperate with the Director to provide necessary drug-related information. The Director reports to the President and Congress on drug use and effectiveness of various programs under the National Drug Control Strategy. The Director reports to the President and Congress on drug use and effectiveness of programs under the National Drug Control Strategy. SEC. 5 amends title 50, United States Code, to include the Director of the Office of National Drug Control Policy as a member of the National Security Council. SEC. 6 establishes the Counter-Drug Technology Assessment Center. The National Narcotics Leadership Act of 1988 is amended to include support for technology in drug treatment and assistance to the Office of National Drug Control Policy. The Director of the Advanced Research Project Agency will provide assistance and support to the Office of National Drug Control Policy under the National Narcotics Leadership Act of 1988 by repealing and redesignating certain sections. SEC. 7. The Director may pay for necessary expenses for consultation on the National Drug Control Strategy. SEC. 8. Authorization of appropriations for fiscal year 1994. SEC. 9. The Office of National Drug Control Policy will terminate on September 30, 1994."
}